Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer-Reference-Cited by-同舟云学术

Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

Published:2003-03 Issue:3 Volume:14 Page:239-246
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:Anti-Cancer Drugs

Author:

Swenson Christine E.,Bolcsak Lois E.,Batist Gerald,Guthrie Troy H.,Tkaczuk Katherine H.,Boxenbaum Harold,Welles Lauri,Chow Shein-Chung,Bhamra Rupinder,Chaikin Philip

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference23 articles.

1. Treatment of Breast Cancer

2. Liposomal Doxorubicin

3. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient

4. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer

5. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome;International Journal of Pharmaceutics;2024-11

2. Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management;Journal of Clinical Medicine;2024-03-09

3. Rapid liposomal formulation for nucleolin targeting to rhabdomyosarcoma cells;European Journal of Pharmaceutics and Biopharmaceutics;2024-01

4. A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma;Blood Advances;2023-08-01

5. Cancer Drug Products Containing Nano-materials: Key Regulatory Issues;Therapeutic Nanocarriers in Cancer Treatment: Challenges and Future Perspective;2023-03-05